Induced Pluripotent Stem Cells
iPSC's Main Innovators
Lonza is a company that has become one of the largest suppliers of the Pharm&Biotech and Specialty Ingredients market. Lonza is also a large supporter of the research on induced pluripotent stem cells. To support researchers, Lonza offers services and products relating to stem cells. Products such as the L7™ System work in the generation, maintenance, expansion, and cryopreservation of induced pluripotent stem cells. While Lonza is a large supporter of stem cell research, it also deals with other subjects such as drug discovery and water filtration.
The video above explains the effects of the L7™ system on somatic stem cells.
​
Stemgent is a company that specializes in the creation of induced pluripotent stem cells for the researchers in induced pluripotency. Their goal is to create stem cells so that the researchers there do not have to use their time and resources creating the stem cells themselves. The stem cells produced by Stemgent are footprint-free and are used in many different areas such as drug discovery. While stem cells are one of their main focuses, Stemgent also work in various other biotech related subjects.
The Cellular Dynamics International company specialize in the creation of two different types of induced pluripotent stem cells. One type of these cells are the iCell®. iCell® is a stem cell engineered to mimic the human biology at homeostasis. The other type of cell is called a MyCell® and can be engineered to have a specific genotype or mimic disease. Cellular Dynamics International also work in the area of drug discovery along with their stem cells.
The video above depicts an iCell working with neurons.
CIRM is a stem cell research facility that works diligently to turn induced pluripotent stem cells into a cure. All research done at CIRN goes towards speeding up research in the stem cell field, curing medical conditions that currently cannot be cured, and increasing stem cell's success rate. CIRM also works to train and educate the next generation of scientists through their internships and programs. They hope to further stem cell reasearch and create new lines of pluripotent stem cell lines.
The CIRM video above describes CIRM's effect on many stem cell research labs and the growth of stem cell research in California.
Fate Therapeutics works using induced pluripotent stem cells to create three hematopoietic cells. These three cells, T cells, hematopoietic cells, and natural killer cells, are created by Fate to be used as therapies for many different conditions such as cancer. Fate Therapeutics change the "fate" of somatic cells using iPSC technology and reconfigure these somatic cells into the three types of cells listed above.
ViaCyte is a regenerative medicine company that specializes in the use of stem cells to create pancreatic beta cell precursors. These cells are then planted into a patient's body using a medical device. When grown, the cells will begin to produce insulin at a regulated pace to control blood sugar levels. This research is being conducted in hopes that patients can be cured from type 1 and type 2 diabetes.
Above is a video trailer for a documentary that follows ViaCyte's progress on creating their cure for diabetes.
ALSTEM Cell Advancements is a start-up biotech company that specializes in the creation and use of induced pluripotent stem cells and iPSC technology. ALSTEM is also one of the few biotech companies to have a special agreement with the iPS Academia Japan which allows them to use the portfolio founded by Dr. Shinya Yamanaka. The company also offers other biotech products such as proteins and the retroviruses needed to make iPSC.
Cynata Therapeutics is a regenerative medicine company that utilizes stem cell technology to create their own therapeutic stem cell platform called Cymerus™. Cymerus™ works in the creation of versatile stem cells called mesenchymoangioblasts (MCAs). The material used to create this cell are adult donor induced pluripotent stem cells. The MCAs can be used to treat diseases ranging from osteoarthiritis to heart disease. With Cynata's new technology, the MCAs can be produced without the need of fresh stem cell donors, making their production to be virtually limitless.
The video above explains stem cells and the Cynata stem cell technology .